Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions
September 29 2022 - 8:00AM
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage
biotechnology company with a mission to discover, develop and
deliver potentially curative therapies that address the underlying
causes of heart disease, announced today that it is scheduled to
participate in the Hypertrophic Cardiomyopathy Medical Society’s
(HCMS) inaugural 2022 Scientific Sessions taking place September
30, 2022, virtually and in National Harbor, MD.
Milind Desai, M.D., MBA, Director of the Center for Hypertrophic
Cardiomyopathy and Director of Clinical Operations, Heart, Vascular
& Thoracic Institute at Cleveland Clinic will present
preclinical data for Tenaya’s TN-201, a gene therapy candidate
intended to correct the underlying genetic cause of HCM, MYBPC3
gene mutations. Variants in the MYBPC3 gene are the most common
genetic cause of HCM, believed to contribute to approximately 20
percent of all HCM cases. Whit Tingley, M.D., Ph.D., Tenaya’s Chief
Medical Officer, will join an industry panel to discuss advances in
genetic therapies and its potential in individuals with HCM.
Details of Tenaya’s participation are as follows:
September 30, 2022Time: 10:50 a.m. – 11:10 a.m. ETSession:
Late-Breaking TrialsTitle: Early Breaking Trial 3 “Gene Therapy
Candidate for Hypertrophic Cardiomyopathy Patients with MYBPC3
Mutation”Presenter: Dr. Milind Desai, Cleveland Clinic
Time: 12:15 p.m. – 12:55 p.m. ETSession: Industry
RoundtableSpeaker: Whit Tingley, M.D., Ph.D., Tenaya
Therapeutics
The HCMS Sessions are intended to highlight the history, major
developments and emerging concepts in hypertrophic cardiomyopathy
(HCM), including learning about genetic forms of HCM and emerging
treatments. A copy of the presentation will be posted to Tenaya’s
website. To view full event programming, please visit the HCMS
website.
About TN-201 for
MYBPC3-associated Hypertrophic
CardiomyopathyTN-201 is an adeno-associated virus-based
gene therapy being developed to treat hypertrophic cardiomyopathy
(HCM) due to disease-causing variants in the Myosin Binding Protein
C3 (MYBPC3) gene. HCM is a chronic, progressive condition in which
the walls of the left ventricle become significantly thickened,
leading to abnormal heart rhythms, cardiac dysfunction, heart
failure and increased risk of sudden cardiac death, accompanied by
symptoms such as shortness of breath, fainting and palpitations.
Variants in MYBPC3 are the most common genetic cause of HCM,
estimated to represent approximately 20 percent of the overall HCM
population and to affect approximately 115,000 patients in the
United States alone. In preclinical studies, following a one-time
injection of TN-201 in a severely diseased knock-out model of
MYBPC3-associated HCM, a reversal of cardiac dysfunction and
improvement in survival was observed. Tenaya plans to submit an
Investigational New Drug application for TN-201 to the U.S. Food
and Drug Administration in the second half of this year.
About Tenaya TherapeuticsTenaya
Therapeutics is a clinical-stage biotechnology company
committed to a bold mission: to discover, develop and deliver
curative therapies that address the underlying drivers of heart
disease. Founded by leading cardiovascular scientists
from Gladstone Institutes and the University of
Texas Southwestern Medical Center, Tenaya is developing therapies
for rare genetic cardiovascular disorders as well as for more
prevalent heart conditions through three distinct but interrelated
product platforms: Gene Therapy, Cellular Regeneration and
Precision Medicine. For more information,
visit www.tenayatherapeutics.com.
InvestorsMichelle CorralTenaya
TherapeuticsIR@tenayathera.com
MediaWendy RyanTen Bridge
Communicationswendy@tenbridgecommunications.com
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Jul 2023 to Jul 2024